hepatocellular carcinoma

Omega Therapeutics adds $126M to move “programmable” drugs closer to the clinic

Omega Therapeutics has raised more than $210 million in the past eight months for R&D of medicines that regulate genes. The company’s lead therapeutic candidate addresses a validated but elusive cancer target.

By Frank Vinluan

BioPharma

Merck’s Keytruda flunks liver cancer confirmatory trial 3 months after accelerated approval

The company said it had shared data from the Phase III study with the FDA. However, per FDA regulations, there is a risk that the accelerated approval for hepatocellular carcinoma could be withdrawn.

By Alaric DeArment

The Funding Model for Cancer Innovation is Broken — We Can Fix It

Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.

By Eve McDavid - CEO of Mission-Driven Tech

Consumer / Employer